These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19017829)

  • 1. Probable interaction between warfarin and torsemide.
    Bird J; Carmona C
    Ann Pharmacother; 2008 Dec; 42(12):1893-8. PubMed ID: 19017829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of torsemide on pharmacodynamics and pharmacokinetics of warfarin in humans and rats.
    Kim HO; Lee KE; Park HY; Lee NR; Oh BR; Chang BC; Gwak HS
    J Pharm Pharmacol; 2013 Aug; 65(8):1195-203. PubMed ID: 23837587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli.
    Spangler ML; Saxena S
    Clin Ther; 2010 Jan; 32(1):53-6. PubMed ID: 20171411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probable warfarin and dapsone interaction.
    Truong T; Haley J
    Clin Appl Thromb Hemost; 2012; 18(1):107-9. PubMed ID: 21890570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probable interaction between warfarin and marijuana smoking.
    Yamreudeewong W; Wong HK; Brausch LM; Pulley KR
    Ann Pharmacother; 2009 Jul; 43(7):1347-53. PubMed ID: 19531696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the effect of torsemide on warfarin dosage requirements.
    Lai S; Momper JD; Yam FK
    Int J Clin Pharm; 2017 Aug; 39(4):831-835. PubMed ID: 28523460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of intolerance to warfarin dosing in an intermediate metabolizer of CYP2C9.
    Lee SY; Kim JS; Kim JW
    Yonsei Med J; 2005 Dec; 46(6):843-6. PubMed ID: 16385662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible interaction between warfarin and Lycium barbarum L.
    Lam AY; Elmer GW; Mohutsky MA
    Ann Pharmacother; 2001 Oct; 35(10):1199-201. PubMed ID: 11675844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement.
    Lee SY; Nam MH; Kim JS; Kim JW
    J Korean Med Sci; 2007 Jun; 22(3):557-9. PubMed ID: 17596671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria.
    Goto T; Miura M; Murata A; Terata K; Uno T; Yamamoto K; Abe Y
    Clin Chim Acta; 2010 Sep; 411(17-18):1375-7. PubMed ID: 20420818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated international normalized ratio associated with use of dronedarone and warfarin.
    Pogge EK; Haber SL
    Ann Pharmacother; 2011 Sep; 45(9):e46. PubMed ID: 21811004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tobacco on INR.
    Garry J; Geraets DR
    Am J Health Syst Pharm; 2007 Apr; 64(8):804; author reply 805. PubMed ID: 17420191
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential interaction between warfarin and high dietary protein intake.
    Hornsby LB; Hester EK; Donaldson AR
    Pharmacotherapy; 2008 Apr; 28(4):536-9. PubMed ID: 18363537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
    Aithal GP; Day CP; Kesteven PJ; Daly AK
    Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenofibrate potentiates warfarin effects.
    Kim KY; Mancano MA
    Ann Pharmacother; 2003 Feb; 37(2):212-5. PubMed ID: 12549950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction potential between cranberry juice and warfarin.
    Pham DQ; Pham AQ
    Am J Health Syst Pharm; 2007 Mar; 64(5):490-4. PubMed ID: 17322161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database.
    Knudsen JF; Sokol GH
    Pharmacotherapy; 2008 Apr; 28(4):540-8. PubMed ID: 18363538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy.
    Avery PJ; Jorgensen A; Hamberg AK; Wadelius M; Pirmohamed M; Kamali F;
    Clin Pharmacol Ther; 2011 Nov; 90(5):701-6. PubMed ID: 22012312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.